JP2023504904A5 - - Google Patents
Info
- Publication number
- JP2023504904A5 JP2023504904A5 JP2022534636A JP2022534636A JP2023504904A5 JP 2023504904 A5 JP2023504904 A5 JP 2023504904A5 JP 2022534636 A JP2022534636 A JP 2022534636A JP 2022534636 A JP2022534636 A JP 2022534636A JP 2023504904 A5 JP2023504904 A5 JP 2023504904A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- arg
- conjugate group
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911250088.1 | 2019-12-09 | ||
| CN201911250088 | 2019-12-09 | ||
| PCT/CN2020/134598 WO2021115272A1 (zh) | 2019-12-09 | 2020-12-08 | 钙敏感受体激动剂化合物及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504904A JP2023504904A (ja) | 2023-02-07 |
| JP2023504904A5 true JP2023504904A5 (https=) | 2023-12-14 |
| JP7796013B2 JP7796013B2 (ja) | 2026-01-08 |
Family
ID=76328843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534636A Active JP7796013B2 (ja) | 2019-12-09 | 2020-12-08 | カルシウム感知受容体アゴニスト化合物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230041996A1 (https=) |
| EP (1) | EP4091623A4 (https=) |
| JP (1) | JP7796013B2 (https=) |
| KR (1) | KR20220110789A (https=) |
| CN (2) | CN114222578B (https=) |
| AU (1) | AU2020399030B2 (https=) |
| BR (1) | BR112022011127A2 (https=) |
| CA (1) | CA3159744A1 (https=) |
| MX (1) | MX2022006892A (https=) |
| TW (1) | TW202122410A (https=) |
| WO (1) | WO2021115272A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022257940A1 (zh) * | 2021-06-08 | 2022-12-15 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
| EP4353248A4 (en) * | 2021-06-08 | 2024-10-23 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | CALCIUM-SENSITIVE RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0407097A (pt) * | 2003-04-23 | 2006-01-24 | Japan Tobacco Inc | Antagonista do casr |
| US8999932B2 (en) * | 2009-07-29 | 2015-04-07 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| EP2643292A1 (en) * | 2010-11-26 | 2013-10-02 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
| JP2014508103A (ja) * | 2010-11-26 | 2014-04-03 | レオ ファーマ アクティーゼルスカブ | カルシウム感知受容体活性化合物 |
| HRP20161566T1 (hr) * | 2011-06-08 | 2017-02-24 | Kai Pharmaceuticals, Inc. | Terapijski agensi za reguliranje serumskog fosfora |
| CN109985228A (zh) * | 2011-11-10 | 2019-07-09 | 凯伊药品公司 | 拟钙剂及其使用方法 |
-
2020
- 2020-12-08 WO PCT/CN2020/134598 patent/WO2021115272A1/zh not_active Ceased
- 2020-12-08 BR BR112022011127A patent/BR112022011127A2/pt unknown
- 2020-12-08 CN CN202080057062.XA patent/CN114222578B/zh active Active
- 2020-12-08 AU AU2020399030A patent/AU2020399030B2/en active Active
- 2020-12-08 CA CA3159744A patent/CA3159744A1/en active Pending
- 2020-12-08 CN CN202410744948.1A patent/CN118496313A/zh active Pending
- 2020-12-08 JP JP2022534636A patent/JP7796013B2/ja active Active
- 2020-12-08 EP EP20899484.8A patent/EP4091623A4/en active Pending
- 2020-12-08 US US17/783,233 patent/US20230041996A1/en active Pending
- 2020-12-08 MX MX2022006892A patent/MX2022006892A/es unknown
- 2020-12-08 TW TW109143251A patent/TW202122410A/zh unknown
- 2020-12-08 KR KR1020227022472A patent/KR20220110789A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5753097B2 (ja) | 肥満の治療 | |
| JP6204369B2 (ja) | カルシウム模倣薬およびその使用方法 | |
| JP7381652B2 (ja) | バース症候群の予防または治療のための方法及び組成物 | |
| JP2022513223A5 (https=) | ||
| CN108472329B (zh) | 多肽刺激免疫系统的用途 | |
| CN101842101A (zh) | 水杨酰苯胺修饰的肽用作口服治疗剂 | |
| JP7213811B2 (ja) | 新規なステープルペプチドおよびその使用 | |
| JP2023504904A5 (https=) | ||
| CN105579054A (zh) | 预防或治疗左心室重塑的方法 | |
| WO2014210062A1 (en) | Methods for the regulation of matrix metalloproteinase expression | |
| AU2012267470B2 (en) | Therapeutic agents for regulating serum phosphorus | |
| EP3003345A1 (en) | Angiotensin peptides in treating marfan syndrome and related disorders | |
| WO2015009414A1 (en) | Methods and compositions for regulating srca2a expression levels in myocardial infarction | |
| AU2012267470A1 (en) | Therapeutic agents for regulating serum phosphorus | |
| US20220257711A1 (en) | PEPTOID-PEPTIDE HYBRID, NMEG-aCGRP, AND ITS USE IN CARDIOVASCULAR DISEASES | |
| HK1196939B (en) | Therapeutic agents for regulating serum phosphorus |